<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873313</url>
  </required_header>
  <id_info>
    <org_study_id>12/ANAES/01</org_study_id>
    <nct_id>NCT01873313</nct_id>
  </id_info>
  <brief_title>Blood Levels of Local Anaesthetic in Knee Arthroplasty</brief_title>
  <acronym>BLOCKS</acronym>
  <official_title>Blood Levels of Local Anaesthetic in Knee Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Strathclyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Golden Jubilee National Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal is to evaluate ropivacaine blood concentrations during and after local&#xD;
      anaesthetic (ropivacaine) infiltration - the Caledonian technique - for total knee&#xD;
      replacement surgery. The investigators plan to measure these levels by testing blood samples&#xD;
      taken over a timed period.&#xD;
&#xD;
      This will allow us to confirm whether the current regimen of local anaesthetic use is within&#xD;
      safe limits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local anaesthetic (LA) toxicity may occur when the blood levels of a drug become particularly&#xD;
      high. There is a need to confirm that the technique is safe to use. In addition, journal case&#xD;
      reports may only describe serious side-effects of toxicity such as abnormal heart rhythms&#xD;
      whilst more subtle clinical signs are rarely reported.&#xD;
&#xD;
      The investigators would like to study whether or not toxic levels may be approached in some&#xD;
      patients or whether more subtle toxicity symptoms and signs are missed. For example,&#xD;
      irregular heartbeat, low blood pressure or confusion/agitation.&#xD;
&#xD;
      Therefore, the investigators intend to study ropivacaine blood levels in patients receiving a&#xD;
      total knee replacement in the Golden Jubilee National Hospital. A series of timed samples&#xD;
      will be taken during the perioperative period. The anaesthesia and surgery will be performed&#xD;
      as routine and no new treatment will be involved. Patient demographics, ropivacaine blood&#xD;
      levels and clinical observations following LA administration will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of ropivacaine</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Plasma levels of ropivacaine were analysed to determine total and free levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical observations</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Clinical observations, including potential symptoms and signs of local anaesthetic toxicity, were recorded at the same time as blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of dysrrhythmias as measured by 24-hour Holter monitoring</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>24-hour Holter monitoring was conducted to detect any potential sequelae of local anaesthetic toxicity</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Arthritis of Knee</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <description>Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Up to 20 blood samples per patient&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing elective knee joint replacement where they will be receiving the&#xD;
        Caledonian technique&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients greater than 65 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a known sensitivity/allergy to ropivacaine or amide-type local&#xD;
             anaesthetics&#xD;
&#xD;
          -  Patients who are not suitable for the Caledonian technique&#xD;
&#xD;
          -  Patients who refuse or are unable to give consent&#xD;
&#xD;
          -  Patients undergoing bilateral hip replacements&#xD;
&#xD;
          -  Patients with known heart, liver or kidney failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gill, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Research Scotland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <state>West Dunbartonshire</state>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

